RKRoland P. Kuiper

Roland P. Kuiper

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Roland P. Kuiper has a total of 113 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Beyond KRAS mutation status: influence of KRAScopy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients

    by Leonie Jm Mekenkamp, Jolien Tol, Jeroen R Dijkstra, Inge de Krijger, M Elisa Vink-Börger, Shannon van Vliet, Steven Teerenstra, Eveline Kamping, Eugène Verwiel, Miriam Koopman, et al.

    Background: KRAS mutation is a negative predictive factor for treatment with anti-epidermal growth factor receptor (EGFR) antibodies in metastatic colorectal cancer (mCRC). Novel predictive markers are required to further improve the selection of patients for this treatment. We assessed the influence of modification of KRAS by gene copy number aberration (CNA) and microRNAs (miRNAs) in correlation to clinical outcome in mCRC patients treated with cetuximab in combination with chemotherapy and bevacizumab. Methods: Formalin-fixed paraffin-embedded primary tumour tissue was used from 34 mCRC patients in a phase III trial, who were selected based upon their good (n = 17) or poor (n = 17) progression-free survival (PFS) upon treatment with cetuximab in combination with capecitabine, oxaliplatin, and bevacizumab. Gene copy number at the KRAS locus was assessed using high resolution genome-wide array CGH and the expression levels of 17 miRNAs targeting KRAS were determined by real-time PCR. Results: Copy number loss of the KRAS locus was observed in the tumour of 5 patients who were all good responders including patients with a KRAS mutation. Copy number gains in two wild-type KRAS tumours were associated with a poor PFS. In KRAS mutated tumours increased miR-200b and decreased miR-143 expression were associated with a good PFS. In wild-type KRAS patients, miRNA expression did not correlate with PFS in a multivariate model. Conclusions: Our results indicate that the assessment of KRAS CNA and miRNAs targeting KRAS might further optimize the selection of mCRC eligible for anti-EGFR therapy.


  • Revertant Somatic Mosaicism by Mitotic Recombination in Dyskeratosis Congenita

    by Marjolijn C.J. Jongmans, Eugene T.P. Verwiel, Yvonne Heijdra, Tom Vulliamy, Eveline J. Kamping, Jayne Y. Hehir-Kwa, Ernie M.H.F. Bongers, Rolph Pfundt, Liesbeth van Emst, Frank N. van Leeuwen, et al.


  • Open Access

    The Origin and Nature of Tightly Clustered BTG1 Deletions in Precursor B-Cell Acute Lymphoblastic Leukemia Support a Model of Multiclonal Evolution

    by Esmé Waanders, Blanca Scheijen, Laurens T. van der Meer, Simon V. van Reijmersdal, Liesbeth van Emst, Yvet Kroeze, Edwin Sonneveld, Peter M. Hoogerbrugge, Ad Geurts van Kessel, Frank N. van Leeuwen, et al.

    Recurrent submicroscopic deletions in genes affecting key cellular pathways are a hallmark of pediatric acute lymphoblastic leukemia (ALL). To gain more insight into the mechanism underlying these deletions, we have studied the occurrence and nature of abnormalities in one of these genes, the B-cell translocation gene 1 (BTG1), in a large cohort of pediatric ALL cases. BTG1 was found to be exclusively affected by genomic deletions, which were detected in 65 out of 722 B-cell precursor ALL (BCP-ALL) patient samples (9%), but not in 109 T-ALL cases. Eight different deletion sizes were identified, which all clustered at the telomeric site in a hotspot region within the second (and last) exon of the BTG1 gene, resulting in the expression of truncated BTG1 read-through transcripts. The presence of V(D)J recombination signal sequences at both sites of virtually all deletions strongly suggests illegitimate RAG1/RAG2-mediated recombination as the responsible mechanism. Moreover, high levels of histone H3 lysine 4 trimethylation (H3K4me3), which is known to tether the RAG enzyme complex to DNA, were found within the BTG1 gene body in BCP-ALL cells, but not T-ALL cells. BTG1 deletions were rarely found in hyperdiploid BCP-ALLs, but were predominant in other cytogenetic subgroups, including the ETV6-RUNX1 and BCR-ABL1 positive BCP-ALL subgroups. Through sensitive PCR-based screening, we identified multiple additional BTG1 deletions at the subclonal level in BCP-ALL, with equal cytogenetic distribution which, in some cases, grew out into the major clone at relapse. Taken together, our results indicate that BTG1 deletions may act as “drivers” of leukemogenesis in specific BCP-ALL subgroups, in which they can arise independently in multiple subclones at sites that are prone to aberrant RAG1/RAG2-mediated recombination events. These findings provide further evidence for a complex and multiclonal evolution of ALL. Recent studies have alluded to the existence of a complex clonal cellular architecture in acute lymphoblastic leukemia (ALL), where multiple subclones contribute to leukemogenesis. Here, we show that in pediatric B-cell precursor ALL (BCP-ALL) monoallelic deletions in the tumor suppressor BTG1 locus, which were found to occur in 9% of the patients studied, result in truncations of the gene rather than in complete allelic losses. Using both genetic and epigenetic approaches, we show that these deletions most likely originate from illegitimate RAG recombination. Sensitive backtracking using deletion-spanning PCRs revealed that these BTG1 deletions occur in specific BCP-ALL subtypes, with frequencies higher than previously anticipated, often in one minor subclone or in multiple independent subclones within individual patients. Subclones that carry a BTG1 deletion at diagnosis can evolve into the major clone at relapse. These findings link a mechanism of tumor suppressor gene deletion to the multiclonal evolution of ALL.


  • Spindle-Assembly Checkpoint and Gastrointestinal Cancer

    by Richarda M. de Voer, Nicoline Hoogerbrugge, Roland P. Kuiper

    Rio Frio et al. (Dec. 30 issue)1 report on a germline homozygous mutation in the spindle-assembly checkpoint gene BUB1B in a patient with a nonclassic form of the mosaic variegated aneuploidy syndrome, resulting in reduced expression, increased levels of constitutive aneuploidy, and multiple gastrointestinal neoplasms starting at 34 years of age. The spindle-assembly checkpoint complex, which controls proper chromosome segregation, is sensitive to gene dosage.2 Interestingly, we recently encountered a monoallelic deletion, approximately 1.75 Mb, encompassing another important spindle-assembly checkpoint component gene, BUB1, in a patient with a microsatellite-stable colon carcinoma at 37 years of age. Also, in this patient, an increased level of constitutive aneuploidy was observed (in 10 of 32 lymphocyte metaphases [31%]) ( Table 1 ). Sequence analysis did not reveal any pathogenic mutations in the remaining BUB1 allele. Mouse models have shown that reduced expression of Bub1 or Bub1b drives colon tumorigenesis in ApcMin/+ mice,3,4 presumably because of accelerated loss of the Apc+ locus.4 Together, these data strongly suggest that, in addition to recessively inherited syndromes such as the mosaic variegated aneuploidy syndrome, haploinsufficiency of spindle-assembly checkpoint components may underlie early-onset gastrointestinal cancers that may be prevented by surveillance.


  • Recurrence and variability of germline EPCAM deletions in Lynch syndrome

    by Roland P. Kuiper, Lisenka E.L.M. Vissers, Ramprasath Venkatachalam, Danielle Bodmer, Eveline Hoenselaar, Monique Goossens, Aline Haufe, Eveline Kamping, Renée C. Niessen, Frans B.L. Hogervorst, et al.

    Recently, we identified 3′ end deletions in the EPCAM gene as a novel cause of Lynch syndrome. These truncating EPCAM deletions cause allele‐specific epigenetic silencing of the neighboring DNA mismatch repair gene MSH2 in tissues expressing EPCAM. Here we screened a cohort of unexplained Lynch‐like families for the presence of EPCAM deletions. We identified 27 novel independent MSH2‐deficient families from multiple geographical origins with varying deletions all encompassing the 3′ end of EPCAM, but leaving the MSH2 gene intact. Within The Netherlands and Germany, EPCAM deletions appeared to represent at least 2.8% and 1.1% of the confirmed Lynch syndrome families, respectively. MSH2 promoter methylation was observed in epithelial tissues of all deletion carriers tested, thus confirming silencing of MSH2 as the causative defect. In a total of 45 families, 19 different deletions were found, all including the last two exons and the transcription termination signal of EPCAM. All deletions appeared to originate from Alu‐repeat mediated recombination events. In 17 cases regions of microhomology around the breakpoints were found, suggesting nonallelic homologous recombination as the most likely mechanism. We conclude that 3′ end EPCAM deletions are a recurrent cause of Lynch syndrome, which should be implemented in routine Lynch syndrome diagnostics. Hum Mutat 32:1–8, 2011.


  • Open Access

    Identification of candidate predisposing copy number variants in familial and early‐onset colorectal cancer patients

    by Ramprasath Venkatachalam, Eugène T.P. Verwiel, Eveline J. Kamping, Eveline Hoenselaar, Heike Görgens, Hans K. Schackert, J. Han J.M. van Krieken, Marjolijn J.L. Ligtenberg, Nicoline Hoogerbrugge, Ad Geurts van Kessel, et al.

    In the majority of colorectal cancers (CRCs) under clinical suspicion for a hereditary cause, the disease‐causing genetic factors are still to be discovered. To identify such genetic factors we stringently selected a discovery cohort of 41 CRC index patients with microsatellite‐stable tumors. All patients were below 40 years of age at diagnosis and/or exhibited an overt family history. We employed genome‐wide copy number profiling using high‐resolution SNP arrays on germline DNA, which resulted in the identification of novel copy number variants (CNVs) in six patients (15%) encompassing, among others, the cadherin gene CDH18, the bone morphogenetic protein antagonist family gene GREM1, and the breakpoint cluster region gene BCR. In addition, two genomic deletions were encountered encompassing two microRNA genes, hsa‐mir‐491/KIAA1797 and hsa‐mir‐646/AK309218. None of these CNVs has previously been reported in relation to CRC predisposition in humans, nor were they encountered in large control cohorts (>1,600 unaffected individuals). Since several of these newly identified candidate genes may be functionally linked to CRC development, our results illustrate the potential of this approach for the identification of novel candidate genes involved in CRC predisposition.


  • Micro-RNA copy number abnormalities in familial colorectal cancer

    by Avanita S. Prabowo, Ramprasath Venkatachalam, Eveline Kamping, Marjolijn J. Ligtenberg, Nicoline Hoogerbrugge, Ad Geurts van Kessel, Roland P. Kuiper

  • Noonan syndrome, the SOS1 gene, and embryonal rhabdomyosarcoma

    by Marjolijn C.J. Jongmans, Peter M. Hoogerbrugge, Linda Hilkens, Uta Flucke, Ineke van der Burgt, Kees Noordam, Martina Ruiterkamp-Versteeg, Helger G. Yntema, Willy M. Nillesen, Marjolijn J.L. Ligtenberg, et al.

  • Germline copy number variation and cancer risk

    by Roland P Kuiper, Marjolijn Jl Ligtenberg, Nicoline Hoogerbrugge, Ad Geurts van Kessel


  • IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL

    by R P Kuiper, E Waanders, V H J van der Velden, S V van Reijmersdal, R Venkatachalam, B Scheijen, E Sonneveld, J J M van Dongen, A J P Veerman, F N van Leeuwen, et al.

    Relapse is the most common cause of treatment failure in pediatric acute lymphoblastic leukemia (ALL) and is often difficult to predict. To explore the prognostic impact of recurrent DNA copy number abnormalities on relapse, we performed high-resolution genomic profiling of 34 paired diagnosis and relapse ALL samples. Recurrent lesions detected at diagnosis, including PAX5, CDKN2A and EBF1, were frequently absent at relapse, indicating that they represent secondary events that may be absent in the relapse-prone therapy-resistant progenitor cell. In contrast, deletions and nonsense mutations in IKZF1 (IKAROS) were highly enriched and consistently preserved at the time of relapse. A targeted copy number screen in an unselected cohort of 131 precursor B-ALL cases, enrolled in the dexamethasone-based Dutch Childhood Oncology Group treatment protocol ALL9, revealed that IKZF1 deletions are significantly associated with poor relapse-free and overall survival rates. Separate analysis of ALL9-treatment subgroups revealed that non-high-risk (NHR) patients with IKZF1 deletions exhibited a ~12-fold higher relative relapse rate than those without IKZF1 deletions. Consequently, IKZF1 deletion status allowed the prospective identification of 53% of the relapse-prone NHR-classified patients within this subgroup and, therefore, serves as one of the strongest predictors of relapse at the time of diagnosis with high potential for future risk stratification.